MicroRNA‑138 inhibits SOX12 expression and the proliferation, invasion and migration of ovarian cancer cells

Qu,Miaomiao; Zhu,Yongning; Jin,Meng

doi:10.3892/etm.2018.6375

MicroRNA‑138 inhibits SOX12 expression and the proliferation, invasion and migration of ovarian cancer cells

Authors:
- Miaomiao Qu
- Yongning Zhu
- Meng Jin
View Affiliations

Affiliations: Department of Obstetrics, The Affiliated Hospital of Jining Medical University, Jining, Shandong 272100, P.R. China, Department of Gastrointestinal Surgery, The Affiliated Hospital of Jining Medical University, Jining, Shandong 272100, P.R. China
Published online on: June 29, 2018 https://doi.org/10.3892/etm.2018.6375
Pages: 1629-1638
Copyright: © Qu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression and biological functions of microRNA (miR)‑138 in ovarian cancer at the tissue and cellular levels, as well as its underlying mechanisms. A total of 47 patients with ovarian cancer were included in the present study. Ovarian cancer tissues were subjected to staging classification according to the FIGO 2000 criteria. Lymphatic metastasis was also examined. Ovarian cancer A2780 cells were transfected using liposomes. Reverse transcription‑quantitative polymerase chain reaction was used to measure the expression of miR‑138. A Cell‑Counting Kit 8 assay was used to examine cell viability, while a Transwell assay was employed to study cell invasion and migration. The effects of miR‑138 on SOX12 protein expression were examined by western blot analysis. A dual luciferase reporter assay was performed to identify the direct interaction between miR‑138 and SOX12 gene. Expression of miR‑138 was downregulated in ovarian cancer tissues. The level of miR‑138 in patients with ovarian cancer with lymphatic metastasis was significantly lower compared with patients without lymphatic metastasis. However, expression of miR‑138 was not associated with the stage of ovarian cancer. Upregulation of miR‑138 inhibited the proliferation and suppressed the invasion and migration of A2780 cells. SOX12 promoted the proliferation, invasion and migration of A2780 cells. In addition, miR‑138 downregulated the expression of SOX12 via binding with the 3'‑UTR of SOX12 gene. The present study demonstrates that miR‑138 expression is downregulated in ovarian cancer tissues and miR‑138 acts as a tumor suppressor gene by inhibiting SOX12 expression and the proliferation, invasion and migration of ovarian cancer cells.

View Figures

View References

1	Lam SS, Ip CK, Mak AS and Wong AS: A novel p70 S6 kinase-microRNA biogenesis axis mediates multicellular spheroid formation in ovarian cancer progression. Oncotarget. 7:38064–38077. 2016. View Article : Google Scholar : PubMed/NCBI
2	Querleu D, Meurette J, Darai E, Morice P and Planchamp F: Surgical management of ovarian cancer: Trends in clinical practice. Bull Cancer. 103:935–940. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
3	Wen B, Campbell KR, Tilbury K, Nadiarnykh O, Brewer MA, Patankar M, Singh V, Eliceiri KW and Campagnola PJ: 3D texture analysis for classification of second harmonic generation images of human ovarian cancer. Sci Rep. 6:357342016. View Article : Google Scholar : PubMed/NCBI
4	Yang Z, Xu S, Jin P, Yang X, Li X, Wan D, Zhang T, Long S, Wei X, Chen G, et al: MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis. Oncotarget. 7:37649–37663. 2016.PubMed/NCBI
5	Correa DD, Root JC, Kryza-Lacombe M, Mehta M, Karimi S, Hensley ML and Relkin N: Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: Apilot study. Brain Imaging Behav. 11:1652–1663. 2017. View Article : Google Scholar : PubMed/NCBI
6	Tomar T, de Jong S, Alkema NG, Hoekman RL, Meersma GJ, Klip HG, van der Zee AG and Wisman GB: Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Genome Med. 8:1072016. View Article : Google Scholar : PubMed/NCBI
7	Harada T, Nakamura Y, Sato K, Nagaya T, Okuyama S, Ogata F, Choyke PL and Kobayashi H: Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer. Oncotarget. 7:79408–79416. 2016. View Article : Google Scholar : PubMed/NCBI
8	Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, Hershman DL, Wright JD, Shih YT, Nguyen PL and Hu JC: Prognostic significance of digital rectal examination and prostate specific antigen in the prostate, lung, colorectal, and ovarian cancer screening arm. J Urol. 197:363–368. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ren F, Shen J, Shi H, Hornicek FJ, Kan Q and Duan Z: Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer. Biochim Biophys Acta. 1866:266–275. 2016.PubMed/NCBI
10	Salerno L, Marchetti C, Bevilacqua E, Musella A, Riganelli L, Ruscito I, Perniola G, Muzii L and Panici Benedetti P: Beyond the beyond: First case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: Case report. Tumori. 102 Suppl 2:53012016.
11	Matikas A, Syrigos KN and Agelaki S: Circulating biomarkers in non-small-cell lung cancer: Current status and future challenges. Clin Lung Cancer. 17:507–516. 2016. View Article : Google Scholar : PubMed/NCBI
12	Li X, Wainscott C and Xi Y: MicroRNA provides insight into understanding esophageal cancer. Thorac Cancer. 2:134–142. 2011. View Article : Google Scholar : PubMed/NCBI
13	Giza DE, Fuentes-Mattei E, Bullock MD, Tudor S, Goblirsch MJ, Fabbri M, Lupu F, Yeung SJ, Vasilescu C and Calin GA: Cellular and viral microRNAs in sepsis: Mechanisms of action and clinical applications. Cell Death Differ. 23:1906–1918. 2016. View Article : Google Scholar : PubMed/NCBI
14	Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer - an emerging concept. EbioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
15	Shen B, Yu S, Zhang Y, Yuan Y, Li X, Zhong J and Feng J: miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets Ther. 9:6009–6019. 2016. View Article : Google Scholar : PubMed/NCBI
16	Tan Y, Hu H, Tan W, Jin L, Liu J and Zhou H: MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1. Mol Med Rep. 14:4422–4428. 2016. View Article : Google Scholar : PubMed/NCBI
17	Liu Y, Zhang W, Liu K, Liu S, Ji B and Wang Y: miR-138 suppresses cell proliferation and invasion by inhibiting SOX9 in hepatocellular carcinoma. Am J Transl Res. 8:2159–2168. 2016.PubMed/NCBI
18	Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F and Shen S: The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 7:45370–45384. 2016.PubMed/NCBI
19	Yeh YM, Chuang CM, Chao KC and Wang LH: MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer. 133:867–878. 2013. View Article : Google Scholar : PubMed/NCBI
20	Meng Q, Duan P, Li L and Miao Y: Expression of placenta growth factor is associated with unfavorable prognosis of advanced-stage serous ovarian cancer. Tohoku J Exp Med. 244:291–296. 2018. View Article : Google Scholar : PubMed/NCBI
21	Brown RAM, Epis MR, Horsham JL, Kabir TD, Richardson KL and Leedman PJ: Total RNA extraction from tissues for microRNA and target gene expression analysis: Not all kits are created equal. BMC Biotechnol. 18:162018. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Paris PL, Chen J, Ngo V, Yao H, Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, et al: Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett. 356:404–409. 2015. View Article : Google Scholar : PubMed/NCBI
24	Chao A, Lai CH, Chen HC, Lin CY, Tsai CL, Tang YH, Huang HJ, Lin CT, Chen MY, Huang KG, et al: Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol. 53:536–541. 2014. View Article : Google Scholar : PubMed/NCBI
25	Wang FF, Wang S, Xue WH and Cheng JL: microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9. Mol Cell Biochem. 423:29–37. 2016. View Article : Google Scholar : PubMed/NCBI
26	Sathyanarayanan A, Chandrasekaran KS and Karunagaran D: microRNA-146a inhibits proliferation, migration and invasion of human cervical and colorectal cancer cells. Biochem Biophys Res Commun. 480:528–533. 2016. View Article : Google Scholar : PubMed/NCBI
27	Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang JR, Han XJ, Zhu SJ, Wang SM, Li YH and Zhang W: miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer. 16:8062016. View Article : Google Scholar : PubMed/NCBI
28	Nagase S, Iyoda T, Kanno H, Akase T, Arakawa I, Inoue T and Uetsuka Y: Comparison of the cost-effectiveness of the sox and cox regimens in patients with unresectable advanced and recurrent colorectal cancer using a clinical decision analysis approach. Gan To Kagaku Ryoho. 43:1201–1205. 2016.(In Japanese). PubMed/NCBI
29	Righi S, Pileri S, Agostinelli C, Bacci F, Spagnolo S and Sabattini E: Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. Hum Pathol. 59:94–101. 2017. View Article : Google Scholar : PubMed/NCBI
30	Fu L and Shi YB: The Sox transcriptional factors: Functions during intestinal development in vertebrates. Semin Cell Dev Biol. 63:58–67. 2017. View Article : Google Scholar : PubMed/NCBI
31	Weina K, Wu H, Knappe N, Orouji E, Novak D, Bernhardt M, Hüser L, Larribère L, Umansky V, Gebhardt C and Utikal J: TGF-β induces SOX2 expression in a time-dependent manner in human melanoma cells. Pigment Cell Melanoma Res. 29:453–458. 2016. View Article : Google Scholar : PubMed/NCBI
32	Song WS, Yang YP, Huang CS, Lu KH, Liu WH, Wu WW, Lee YY, Lo WL, Lee SD, Chen YW, et al: Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chin Med Assoc. 79:538–545. 2016. View Article : Google Scholar : PubMed/NCBI
33	Li N and Li S: Epigenetic inactivation of SOX1 promotes cell migration in lung cancer. Tumour Biol. 36:4603–4610. 2015. View Article : Google Scholar : PubMed/NCBI
34	Gambichler T, Petig AL, Stockfleth E and Stucker M: Expression of SOX10, ABCB5 and CD271 in melanocytic lesions and correlation with survival data of patients with melanoma. Clin Exp Dermatol. 41:709–716. 2016. View Article : Google Scholar : PubMed/NCBI
35	Yang M, Cui G, Ding M, Yang W, Liu Y, Dai D and Chen L: miR-935 promotes gastric cancer cell proliferation by targeting SOX7. Biomed Pharmacother. 79:153–158. 2016. View Article : Google Scholar : PubMed/NCBI
36	Liu H, Mastriani E, Yan ZQ, Yin SY, Zeng Z, Wang H, Li QH, Liu HY, Wang X, Bao HX, et al: SOX7 co-regulates Wnt/β-catenin signaling with Axin-2: Both expressed at low levels in breast cancer. Sci Rep. 6:261362016. View Article : Google Scholar : PubMed/NCBI
37	Ding H, Quan H, Yan W and Han J: Silencing of SOX12 by shRNA suppresses migration, invasion and proliferation of breast cancer cells. Biosci Rep. 36:e003892016. View Article : Google Scholar
38	Huang W, Chen Z, Shang X, Tian D, Wang D, Wu K, Fan D and Xia L: Sox12, a direct target of FoxQ1, promotes hepatocellular carcinoma metastasis through up-regulating Twist1 and FGFBP1. Hepatology. 61:1920–1933. 2015. View Article : Google Scholar : PubMed/NCBI